Transcription of 白血病の治療 - chp-kagawa.jp
1 1. 2. 3. de Novo M0 M1 M2 M3 M4 M5 M6 M7 t(8;21) t(15;17) inv 16 AML Blood, 2002t(8;21), t(15.)
2 17), or inv(16)5, del(5q), 7, or 3q abnormalities5 or more unrelated abnormalities M3 PML-RARalpha ATRA 90 70 80 Am80 IDA 10mg/m2 Day AraC 100mg/m2 AraC+IDA1101001000100001000001000000 DAY135710 12 14 16 1819 2123 25 27 28 30 32 WBCB lastNeutLympAraC+IDA 80 90% CR 50% 50-60% CR
3 ALL01/81 VP DNR L-ASP 74 CR CALGB 8811 ALL01/81 + CPM 85 CR hyper-CVAD 91 CR ALL01/81 39 5 CALGB 46 3 hyper-CVAD 38 5 SCT Ph 4 Five Drug L- Blood, Vol. 93 No. 11 (June 1), 1999t(9;22), 7, +8, and t(4;11) J Clin Oncol. 2006 Jan 20;24(3):460-6 t(9.)
4 22) BCR-ABL G FISH PCR Amp-CML) 5 ALL>AML ML 12 STI signal transduction inhibitor) BU+CY STI vs Interferon&AraCSTI ABL ATP CML Ph-ALL 600 800 300mg Bcr-Abl Src Bcr-Abl AMN107 10 30 Bcr-Abl 34
5 Attack !!Attack !! Attack !!Attack !! Attack !!Attack !! Attack !!Attack !! GVHD (graft versus host disease : Attack !!Attack !! GVT (graft versus tumor effect : -772I365I00 028))
